Hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
sulfasalazine	sulfasalazine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
inflammatory	inflammatory	O	O	O	O
arthritis	arthritis	O	DISEASE	OTHERS	I
:	:	O	O	O	O
A	a	O	O	O	O
case	case	O	O	O	O
series	series	O	O	O	O
from	from	O	O	O	O
a	a	O	O	O	O
local	local	O	O	O	O
surveillance	surveillance	O	O	O	O
of	of	O	O	O	O
serious	serious	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Spontaneous	spontaneous	O	O	O	O
reporting	reporting	O	O	O	O
systems	systems	O	O	O	O
for	for	O	O	O	O
adverse	adverse	O	O	OTHERS	I
drug	drug	O	O	OTHERS	I
reactions	reactions	O	O	OTHERS	I
(	(	O	O	O	O
ADRs	adrs	O	O	O	O
)	)	O	O	O	O
are	are	O	O	O	O
handicapped	handicapped	O	O	O	O
by	by	O	O	O	O
under-reporting	under-reporting	O	O	O	O
and	and	O	O	O	O
limited	limited	O	O	O	O
detail	detail	O	O	O	O
on	on	O	O	O	O
individual	individual	O	O	O	O
cases	cases	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
an	an	O	O	O	O
investigation	investigation	O	O	O	O
from	from	O	O	O	O
a	a	O	O	O	O
local	local	O	O	O	O
surveillance	surveillance	O	O	O	O
for	for	O	O	O	O
serious	serious	O	O	O	O
adverse	adverse	O	O	OTHERS	I
drug	drug	O	O	OTHERS	I
reactions	reactions	O	O	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
disease	disease	O	O	O	O
modifying	modifying	O	O	O	O
anti-rheumatic	anti-rheumatic	O	O	O	O
drugs	drugs	O	O	O	O
that	that	O	O	O	O
was	was	O	O	O	O
triggered	triggered	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
occurrence	occurrence	O	O	O	O
of	of	O	O	O	O
liver	liver	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
in	in	O	O	O	O
two	two	O	O	O	O
of	of	O	O	O	O
our	our	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
Serious	serious	O	O	O	O
ADR	adr	CHEMICALS	O	OTHERS	I
reports	reports	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
solicited	solicited	O	O	O	O
from	from	O	O	O	O
local	local	O	O	O	O
clinicians	clinicians	O	O	O	O
by	by	O	O	O	O
regular	regular	O	O	O	O
postcards	postcards	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
past	past	O	O	O	O
seven	seven	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
'	'	O	O	O	O
,	,	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
on	on	O	O	O	O
sulfasalazine	sulfasalazine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
met	met	O	O	O	O
a	a	O	O	O	O
definition	definition	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
serious	serious	O	O	O	O
ADR	adr	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
were	were	O	O	O	O
identified	identified	O	O	O	O
.	.	O	O	O	O

Two	two	O	O	O	O
clinicians	clinicians	O	O	O	O
reviewed	reviewed	O	O	O	O
structured	structured	O	O	O	O
case	case	O	O	O	O
reports	reports	O	O	O	O
and	and	O	O	O	O
assessed	assessed	O	O	O	O
causality	causality	O	O	O	O
by	by	O	O	O	O
consensus	consensus	O	O	O	O
and	and	O	O	O	O
by	by	O	O	O	O
using	using	O	O	O	O
a	a	O	O	O	O
causality	causality	O	O	O	O
assessment	assessment	O	O	O	O
instrument	instrument	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
likely	likely	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
with	with	O	O	O	O
sulfasalazine	sulfasalazine	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
estimated	estimated	O	O	O	O
by	by	O	O	O	O
making	making	O	O	O	O
a	a	O	O	O	O
series	series	O	O	O	O
of	of	O	O	O	O
conservative	conservative	O	O	O	O
assumptions	assumptions	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Ten	ten	O	O	O	O
cases	cases	O	O	O	O
were	were	O	O	O	O
identified	identified	O	O	O	O
:	:	O	O	O	O
eight	eight	O	O	O	O
occurred	occurred	O	O	O	O
during	during	O	O	O	O
surveillance	surveillance	O	O	O	O
.	.	O	O	O	O

Eight	eight	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
hospitalised	hospitalised	O	O	O	O
,	,	O	O	O	O
two	two	O	O	O	O
in	in	O	O	O	O
hepatic	hepatic	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
-	-	O	O	O	O
one	one	O	O	O	O
died	died	O	O	O	O
after	after	O	O	O	O
a	a	O	O	O	O
liver	liver	O	O	O	O
transplant	transplant	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
but	but	O	O	O	O
one	one	O	O	O	O
event	event	O	O	O	O
occurred	occurred	O	O	O	O
within	within	O	O	O	O
6	6	O	O	O	O
weeks	weeks	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Seven	seven	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
skin	skin	O	O	OTHERS	I
rash	rash	O	DISEASE	OTHERS	I
,	,	O	O	O	O
three	three	O	O	O	O
eosinophilia	eosinophilia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
one	one	O	O	O	O
interstitial	interstitial	O	DISEASE	OTHERS	I
nephritis	nephritis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Five	five	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
of	of	O	O	O	O
Black	black	O	O	O	O
British	british	O	O	O	O
of	of	O	O	O	O
African	african	O	O	O	O
or	or	O	O	O	O
Caribbean	caribbean	O	O	O	O
descent	descent	O	O	O	O
.	.	O	O	O	O

Liver	liver	O	O	O	O
enzymes	enzymes	O	O	O	O
showed	showed	O	O	O	O
a	a	O	O	O	O
hepatocellular	hepatocellular	O	O	O	O
pattern	pattern	O	O	O	O
in	in	O	O	O	O
four	four	O	O	O	O
cases	cases	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
mixed	mixed	O	O	O	O
pattern	pattern	O	O	O	O
in	in	O	O	O	O
six	six	O	O	O	O
.	.	O	O	O	O

Drug-related	drug-related	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
judged	judged	O	O	O	O
probable	probable	O	O	O	O
or	or	O	O	O	O
highly	highly	O	O	O	O
probable	probable	O	O	O	O
in	in	O	O	O	O
8	8	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
likely	likely	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
serious	serious	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
with	with	O	O	O	O
sulfasalazine	sulfasalazine	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
estimated	estimated	O	O	O	O
at	at	O	O	O	O
0.4	0.4	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
treated	treated	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Serious	serious	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
sulfasalazine	sulfasalazine	CHEMICALS	O	OTHERS	I
appears	appears	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
under-appreciated	under-appreciated	O	O	O	O
and	and	O	O	O	O
intensive	intensive	O	O	O	O
monitoring	monitoring	O	O	O	O
and	and	O	O	O	O
vigilance	vigilance	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
6	6	O	O	O	O
weeks	weeks	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
is	is	O	O	O	O
especially	especially	O	O	O	O
important	important	O	O	O	O
.	.	O	O	O	O

